ARTICLE | Clinical News
Cerulean preclinical data
September 6, 2010 7:00 AM UTC
In mouse models of cancer, 30 mg/kg twice-weekly CRLX288, a biodegradable polymeric nanoparticle conjugated to docetaxel, led to greater tumor growth delay and survival vs. 15 mg/kg twice-weekly free-...